Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

ributable to common shareholders was $0.03 million, or $0.00 per share, compared to $4.3 million, or $0.14 per share, in the same period of 2010.  The year-over-year decrease in net loss includes the impact of the change in fair value of the Company's derivative instruments, which resulted in a non-cash decrease of expenses of $2.9 million for the three months ended September 30, 2011 compared to a non-cash decrease of expenses of $0.08 million for the same period in 2010. The decrease in fair value realized during the third quarter of 2011 was primarily the result of the decrease in PharmAthene's stock price from $2.94 per share on June 30, 2011 to $1.76 per share on September 30, 2011.

As of September 30, 2011, the Company had cash and cash equivalents, short-term investments, and net U.S. government accounts receivables and other receivables, including unbilled receivables, totaling approximately $16.9 million compared to $21.6 million at December 31, 2010.  The decrease at September 30, 2011 was primarily due to a combination of a loss from operations of $10.6 million, partially offset by proceeds from a registered direct public offering of common stock and warrants completed in June 2011, which raised net proceeds for the Company of $5.8 million, as well as a net reduction in receivables, prepaid expenses and other current assets and noncash expenses."During the quarter we made significant progress across our biodefense countermeasures programs, particularly in our development of our second generation anthrax vaccine, SparVax™," continued Mr. Richman.  "We recently completed the first 1,500 cGMP manufacturing production run as part of the development of a robust manufacturing process.  This is a significant achievement for our Company and enables us to potentially produce more than 150 million rPA vaccine equivalent doses of bulk drug substance at a 50 mcg dose.  We were also awarded a contract valued at $5.7 million
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... the stock of United Kingdom -based ... microbiological culture media and diagnostic systems. ... into a leading provider of microbial testing and diagnostic ... testing markets. The company currently sells into more than ...
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
(Date:8/27/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... genetics and hypertension at the International Academy of Cardiology Annual Scientific ... The event, which boasts an extensive overview of the latest research developments in ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... , , , , , , , ... , 1636138, 1 kit, ... Package Inserts/Product , Instructions , , English , ... version - 39 K , , US Material Safety , ...
... , , , , Here are some troubleshooting hints that we have gathered , if your ... , , , ... , , , , ... template in the reaction is not optimal , , , ...
... , , Here are some troubleshooting hints that we have gathered , ... , , , , ... href="#Option1">Primer annealing temperature is too high , ... , , <a , ...
Cached Biology Technology:Trouble-shooting: No product 2Trouble-shooting: No product 3Trouble-shooting: No product 4Trouble-shooting: No product 5Trouble-shooting: Low yield 2Trouble-shooting: Low yield 3Trouble-shooting: Low yield 4Trouble-shooting: Low yield 5Trouble-shooting: Low yield 6Trouble-shooting: Low yield 7
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2
... ongoing research on biotic invasions around the world constantly ... in the United States shows how using improved data ... species changes the understanding of patterns of species naturalization, ... published in the open access journal NeoBiota ...
... discovered specific molecular and signaling events by which vitamin ... low levels of Vitamin D, comparable to levels found ... cascade, while levels considered adequate did inhibit inflammatory signaling. ... issue of The Journal of Immunology . , ...
... the potential severity of an outbreak of airborne H5N1 influenza ... instead on how we can safely continue H5N1 research and ... be published in mBio , the online open-access journal ... H5N1 influenza has been at the center of heated ...
Cached Biology News:Human population the primary factor in exotic plant invasions in the United States 2Researchers discover how vitamin D inhibits inflammation 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 3
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: